Regional advisory board position statement on optimal pneumococcal vaccination in adults. Update to 2011 consensus on adult pneumococcal disease: update on optimal pneumococcal vaccination in adults
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24592732
DOI
10.21101/cejph.a3959
Knihovny.cz E-resources
- MeSH
- Middle Aged MeSH
- Humans MeSH
- Pneumococcal Infections immunology prevention & control MeSH
- Pneumococcal Vaccines administration & dosage immunology MeSH
- Practice Guidelines as Topic MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe MeSH
- Israel MeSH
- Names of Substances
- 13-valent pneumococcal vaccine MeSH Browser
- Pneumococcal Vaccines MeSH
BACKGROUND: An important development in the field of adult pneumococcal vaccination since the last Consensus Statement, published by the Expert Panel of Central and Eastern Europe and Israel (the Region) in September 2012, was the licensure of the 13-valent pneumococcal conjugate vaccine (PCV13) for adults aged 50 years and older. DISCUSSION: The Expert Panel has developed this Position Statement as an update to its previous Consensus to address the following topics which are likely to be on the agenda of national scientific societies during the ongoing updates of vaccination recommendations in the Region: the availability of a pneumococcal conjugate vaccine for adults over 50 years of age, the available clinical evidence on its use in adults, and the future place of conjugate vaccines in adult pneumococcal vaccination. The Expert Panel concluded that there is sufficient epidemiologic immunogenicity and safety evidence to use PCV 13 in adults over 50 years of age. RESULTS: The use of conjugate vaccine induces immunological memory and can overcome some limitations associated with the plain polysaccharide vaccine (PPV). It was also agreed that, if the use of PPV is considered appropriate, PCV13 should be administered first, regardless of prior pneumococcal vaccination status.
Department of Chest Diseases Ege University Medical Faculty Izmir Turkey
Institute of Antimicrobial Chemotherapy Smolensk State Medical Academy Smolensk Russia
lnfectious Disease Unit Sheba Medical Centre Tel Hashomer Ramat Gan Israel
National Institute of Child Health Szent Laszlo Hospital for Infectious Diseases Budapest Hungary
Pulmonology and Phthisiatry Clinic University Hospital Pleven Bulgaria
References provided by Crossref.org